Compare Circle Internet Group Inc. Class A Common Stock (CRCL) vs Nuvation Bio Inc. Class A Common Stock (NUVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Circle Internet Group Inc. Class A Common Stock vs Nuvation Bio Inc. Class A Common Stock — how do they compare? Circle Internet Group Inc. Class A Common Stock trades at $84.72 (market cap $20.52B), while Nuvation Bio Inc. Class A Common Stock trades at $5 (market cap $1.74B). The key difference: Circle Internet Group Inc. Class A Common Stock is far larger — about 11.8× Nuvation Bio Inc. Class A Common Stock's market cap, and Circle Internet Group Inc. Class A Common Stock is more actively traded (9,813,610 versus 9,289,619). Which is the better fit depends on your goals — on Pluang, investors hold Circle Internet Group Inc. Class A Common Stock for 0 Days and Nuvation Bio Inc. Class A Common Stock for 1 Days on average.
| CRCL | NUVB | |
|---|---|---|
Market Cap | $20.52B | $1.74B |
Volume | 9,813,610 | 9,289,619 |
Sector | Financials | Health |
52-Week High | $150.48 | $9.54 |
52-Week Low | $50.23 | $3.41 |
Typical Hold Time | 0 Days | 1 Days |
Enterprise Value | $19.03B | $1.33B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Circle Internet Group Inc. Class A Common Stock
Circle Internet Group provides internet financial infrastructure centered on its stablecoin network. Its business includes stablecoins, blockchain infrastructure for developers, digital-asset services, and payment applications.
Read more on CRCL →About Nuvation Bio Inc. Class A Common Stock
Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →
